Clinical trial
Abatacept With Methotrexate- Phase IIB
NCT00162266 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00162266 |
|---|---|
| Title | Abatacept With Methotrexate- Phase IIB |
| Official title | A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Abatacept (BMS-188667), Placebo |
| Enrollment | 524 |
| Start date | Oct 1, 2000 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 1, 2009 |
| First posted | Sep 13, 2005 |
| Last update posted | Jun 1, 2012 |
| Countries | Argentina, Australia, Belgium, Canada, France, Germany, Ireland, Netherlands, South Africa, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: